Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,349,146
  • Shares Outstanding, K 101,475
  • Annual Sales, $ 63,520 K
  • Annual Income, $ -376,740 K
  • EBIT $ -446 M
  • EBITDA $ -447 M
  • 60-Month Beta 2.40
  • Price/Sales 36.86
  • Price/Cash Flow N/A
  • Price/Book 2.42

Options Overview Details

View History
  • Implied Volatility 82.36% ( -3.42%)
  • Historical Volatility 80.20%
  • IV Percentile 75%
  • IV Rank 44.92%
  • IV High 119.34% on 05/06/25
  • IV Low 52.20% on 08/06/25
  • Put/Call Vol Ratio 1.89
  • Today's Volume 101
  • Volume Avg (30-Day) 1,552
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 34,015
  • Open Int (30-Day) 24,286

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.09
  • Number of Estimates 5
  • High Estimate -0.90
  • Low Estimate -1.24
  • Prior Year -1.09
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.70 +1.34%
on 11/07/25
31.54 -30.28%
on 10/21/25
-3.14 (-12.50%)
since 10/07/25
3-Month
15.60 +40.96%
on 08/21/25
31.54 -30.28%
on 10/21/25
+4.13 (+23.12%)
since 08/07/25
52-Week
13.52 +62.59%
on 04/07/25
35.25 -37.62%
on 02/18/25
-4.11 (-15.75%)
since 11/07/24

Most Recent Stories

More News
2 Stocks to Buy Now to Profit from the Rise of Robotics

Investors betting on the future of automation in high-tech manufacturing would do well to keep these two stocks on their radar.

BEAM : 21.62 (-6.61%)
LCID : 17.78 (-1.00%)
ROK : 369.00 (-0.94%)
BA : 193.46 (-1.55%)
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026...

BEAM : 21.62 (-6.61%)
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 21.62 (-6.61%)
H.C. Wainwright Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics today and set a price target of $80.00. The company’s shares closed yesterday at $27.87.Elevate Your Investing Strategy:...

BEAM : 21.62 (-6.61%)
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 21.62 (-6.61%)
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 21.62 (-6.61%)
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

Beam Therapeutics BEAM incurred a loss of $1.00 per share in the second quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.04. The company had reported a loss of $1.11...

BEAM : 21.62 (-6.61%)
IMCR : 31.81 (+0.70%)
ARVN : 9.84 (-1.60%)
CRMD : 10.65 (-1.21%)
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile ...

BEAM : 21.62 (-6.61%)
Innovation ETF (ARKK) Hits New 52-Week High

For investors seeking momentum, ARK Innovation ETF ARKK is probably on the radar. The fund just hit a 52-week high and is up about 92.4% from its 52-week low price of $36.85/share. But are more gains...

BEAM : 21.62 (-6.61%)
ROKU : 99.53 (-5.05%)
CRSP : 53.14 (-6.13%)
MASS : 7.49 (-3.97%)
ARKK : 78.22 (-3.34%)
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

BEAM : 21.62 (-6.61%)
INSP : 80.61 (-3.82%)
LFMD : 5.05 (-3.99%)
KRYS : 193.51 (-3.23%)
OPCH : 27.18 (+0.52%)
VEEV : 289.49 (-0.59%)
TMDX : 116.05 (-7.15%)
PODD : 320.56 (-0.88%)
CERT : 9.41 (-16.50%)
TEM : 67.89 (-5.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 24.87
2nd Resistance Point 24.14
1st Resistance Point 23.64
Last Price 21.62
1st Support Level 22.41
2nd Support Level 21.68
3rd Support Level 21.18

See More

52-Week High 35.25
Fibonacci 61.8% 26.95
Fibonacci 50% 24.39
Fibonacci 38.2% 21.82
Last Price 21.62
52-Week Low 13.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar